Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
239.52%
-
Total 13F principal
-
$105,572,796
-
Principal change
-
-$1,248,204
-
Total reported market value
-
$252,922,195
-
Number of holders
-
15
-
Value change
-
+$25,158,974
-
Number of buys
-
10
-
Number of sells
-
5
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q2 2023
As of 30 Jun 2023,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
15 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$105,572,796
in principal (par value) of the bond.
The largest 10 bondholders included
DeepCurrents Investment Group LLC, LAZARD ASSET MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, LORD, ABBETT & CO. LLC, LORD, ABBETT & CO. LLC, CITADEL ADVISORS LLC, Linden Advisors LP, Voya Investment Management LLC, D. E. Shaw & Co., Inc., and JPMORGAN CHASE & CO.
This page lists
16
institutional bondholders reporting positions
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.